{"id":"W3198912637","doi":"10.1158/1078-0432.ccr-21-1466","title":"FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; National Institutes of Health","keywords":"Nivolumab; Ipilimumab; Regimen; Pemetrexed; Carboplatin; Gemcitabine; Chemotherapy regimen; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002335799,0.0005625914,0.000466046,0.000731655,0.0005738818,0.001178455,0.0008588527,0.003016968,0.0161407],"category_scores_gemma":[0.002120024,0.0002286322,0.000902918,0.0005964416,0.0003957081,0.0005008846,0.0002960167,0.001793518,0.007594123],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009793218,"about_ca_system_score_gemma":0.002082217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002011689,"about_ca_topic_score_gemma":0.006489152,"domain_scores_codex":[0.9990908,0.0002725251,0.00005041088,0.0001113067,0.000368099,0.0001068053],"domain_scores_gemma":[0.9985423,0.0002634979,0.0002168533,0.00006456093,0.0005817181,0.0003310988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003410119,0.0007021707,0.002476482,0.00112695,0.000172941,0.0008093619,0.0001130814,0.0004680214,0.01665601,0.002659938,0.6664355,0.3049694],"study_design_scores_gemma":[0.005086366,0.005702025,0.02560979,0.001003599,0.0003113267,0.001324595,0.00005456827,0.001150333,0.003909968,0.0006347933,0.9551601,0.00005242382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.1464641,0.08674134,0.009876743,0.09398837,0.01565937,0.006104321,0.02624482,0.004245053,0.6106759],"genre_scores_gemma":[0.5108645,0.04107083,0.01315321,0.07743388,0.01182519,0.002722513,0.03063881,0.0005307954,0.3117602],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0161407,"threshold_uncertainty_score":0.05399603,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1791777639283689,"score_gpt":0.4791178402547532,"score_spread":0.2999400763263843,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}